Table 2.
Clinicopathologic data and VETC expression of 174 HCC patients in univariate and multivariate regression analysis.
| Variable | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p Value | HR | 95% CI | p Value | |
| Age (yrs) >70 (20.1%) vs. ≤70 (79.9%) |
1.767 | 1.109–2.818 | 0.017 | 1.535 | 0.925–2.548 | 0.097 |
| Sex (M/F) F (28.2%) vs. M (71.8%) |
0.735 | 0.459–1.177 | 0.199 | |||
| Comorbidity Yes (51.1%) vs. No (48.9%) |
1.101 | 0.733–1.654 | 0.644 | |||
| Hepatectomy Major (18.4%) vs. Minor (81.6%) |
1.567 | 0.670–1.919 | 0.638 | |||
| ICGR15 (15%) High (18.8%) vs. Low (81.2%) |
1.885 | 1.164–3.052 | 0.010 * | 2.056 | 1.151–3.673 | 0.015 * |
| Complication Yes (13.5%) vs. No (86.5%) |
1.681 | 0.960–2.945 | 0.069 | |||
| OP time (300 min) More (32.8%) vs. less (67.2%) |
1.233 | 0.809–1.881 | 0.330 | |||
| Blood Loss (500 mL) More (25.0%) vs. less (75.0%) |
1.651 | 1.063–2.564 | 0.026 | 1.115 | 0.681–1.824 | 0.666 |
| Tumor size (cm) >5.0 (16.7%) vs. ≤5.0 (83.3%) |
1.833 | 1.105–3.040 | 0.019 * | 1.510 | 0.821–2.780 | 0.185 |
| Satellite lesions (%) Yes (12.6%) vs. no (87.4%) |
1.354 | 0.753–2.433 | 0.311 | |||
| Vascular invasion (%) Gross (5.2%) vs. Micro (17.2%) vs. No (77.6%) |
1.856 | 1.334–2.582 | <0.001 *** | 1.230 | 0.783–1.934 | 0.369 |
| Grading I/II/III, IV (%) III, IV (38.5%) vs. I, II (63.5%) |
1.606 | 1.068–2.417 | 0.023 * | 1.724 | 1.111–2.674 | 0.015 * |
| Cirrhosis (%) Yes (41.4%) vs. no (58.6%) |
1.656 | 1.071–2.558 | 0.023 * | 1.704 | 1.058–2.747 | 0.028 * |
| Encapsulation Yes (89.1%) vs. no (10.9%) |
1.069 | 0.569–2.006 | 0.836 | |||
| a-fetal protein; AFP (200 ng/mL) >200 (16.7%) vs. ≤200 (83.3%) |
1.482 | 0.875–2.512 | 0.143 | |||
| AJCC 8th Stage a II/III (33.3%) vs. IB (48.3%) vs. IA (18.4%) |
1.728 | 1.270–2.350 | <0.001 *** | 1.322 | 0.892–1.961 | 0.165 |
| AST (IU/L) 2ULN >68 (21.8%) vs. ≤68 (78.2%) |
1.921 | 1.226–3.010 | 0.004 | 0.815 | 0.375–1.771 | 0.605 |
| ALT (IU/L) 2ULN >72 (25.9%) vs. ≤72 (74.1%) |
1.898 | 1.236–2.915 | 0.003 | 1.819 | 0.915–3.617 | 0.088 |
| ALP (IU/L) >100 (18.4%) vs. ≤100 (81.6%) |
1.511 | 0.929–2458 | 0.096 | |||
| ALB (g/dl) >3.5 (94.8%) vs. ≤3.5 (5.2%) |
0.505 | 0.220–1.158 | 0.107 | |||
| VETC Positive (30.5%) vs. Negative (69.5%) |
1.714 | 1.126–2.609 | 0.012 | 2.066 | 1.280–3.337 | 0.003 * |
* statistical significance (p < 0.05) and *** for p < 0.001; HR, hazard ratio; 95% CI, 95% confidence interval of hazard ratio. Disease-free survival was calculated by univariate and multivariate Cox regression analysis. a: American Joint Committee on Cancer, 8th tumor staging.